Altimmune, Inc. (ALT) Form 8-K — Sep 29, 2026
Altimmune appointed Richard Menziuso as VP, Global Controller and Principal Accounting Officer effective September 29, 2026. Menziuso brings 28 years of finance and accounting experience, most recently as Corporate Controller of Centessa Pharmaceuticals until its 2026 acquisition by Eli Lilly, with earlier roles at Thermo Fisher Scientific and Axovant Gene Therapies.
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.